key: cord-0732950-le35ak9m authors: Coste, A. T.; Jaton, K.; Papadimitriou-Olivgeris, M.; Greub, G.; Croxatto, A. title: Comparison of SARS-CoV-2 serological tests with different antigen targets date: 2020-07-10 journal: nan DOI: 10.1101/2020.07.09.20149864 sha: c4a4c342ad53cc9e084de68d2fe4772a52cd6f5f doc_id: 732950 cord_uid: le35ak9m Background These last months, dozens of SARS-CoV-2 serological tests have become available with varying performances. A major effort was completed to compare 17 serological tests. Methods In a preliminary phase, we compared 17 IgG, IgM, IgA and pan Ig serological tests including ELISA, LFA, CLIA and ECLIA on a panel of 182 sera, comprising 113 sera from hospitalized patients with a positive RT-PCR, and 69 sampled before 1st November 2019, expected to give a positive and negative results, respectively. In a second phase, the five best performing and most available tests were further evaluated on a total of 582 sera (178 and 404 expected positive and negative, respectively), allowing the assessment of 20 possible cross-reactions with other virus. Results In the preliminary phase, among eight IgG/pan-Ig ELISA or CLIA/ECLIA tests, four had a sensitivity and specificity above 90% and 98% respectively, and on six IgM/IgA tests, only one was acceptable. Only one LFA test on three showed good performances for both IgG and IgM. For all the tests IgM and IgG aroused concomitantly. In the second phase, no tests showed particular cross-reaction. We observed an important heterogeneity in the development of the antibody response, and that anti-nucleocapside (anti-N) antibodies appeared earlier than the anti-spike (anti-S) proteins. Conclusions The identified SARS-CoV-2 serology tests may be used for the diagnostic of CoviD-19 for negative RT-PCR patients presenting severe to mild suggestive symptoms or particular clinical presentation. Detection of both anti-N and anti-S could be complementary to increase the sensitivity of the analysis. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. T h e i d e n t i f i e d S A R S -C o V -2 s e r o l o g y t e s t s m a y b e u s e d f o r t h e d i a g n o s t i c o f C o v i D -1 9 f o r 59 n e g a t i v e R T -P C R p a t i e n t s p r e s e n t i n g s e v e r e t o m i l d s u g g e s t i v e s y m p t o m s o r p a r t i c u l a r 60 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2020. c l i n i c a l p r e s e n t a t i o n . D e t e c t i o n o f b o t h a n t i -N a n d a n t i -S c o u l d b e c o m p l e m e n t a r y t o 61 i n c r e a s e t h e s e n s i t i v i t y o f t h e a n a l y s i s . 62 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2020. I n t r o d u c t i o n 63 I n D e c e m b e r 2 0 1 9 , a n e w v i r u s c a u s i n g s e v e r e r e s p i r a t o r y i n f e c t i o n s e m e r g e d i n C h i n a i n t h e 64 W u h a n a r e a . T h i s v i r u s w a s n a m e d S A R S -C o V -2 ( S e v e r e A c u t e R e s p i r a t o r y S y n d r o m e 65 C o r o n a v i r u s 2 ) a n d t h e a s s o c i a t e d d i s e a s e w a s c o i n e d " C O V I D -1 9 " ( C O r o n a V I r u s D i s e a s e 66 2 0 1 9 ) . T h e e p i d e m i c r a p i d l y s p r e a d a n d t h e W H O c l a s s i f i e d i t a s a p a n d e m i c i n M a r c h 2 0 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. S w i t z e r l a n d ) . 125 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. 156 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. T h e o n l y I g M / I g A t e s t s p e r f o r m e d a t l e a s t 1 5 d a y s f r o m s y m p t o m s o n s e t , e x h i b i t i n g 157 s a t i s f y i n g p e r f o r m a n c e s w e r e t h e N A D A L L F A ( s e n s i t i v i t y 9 5 % , 9 5 % C I : 8 0 -9 9 ; s p e c i f i c i t y : 158 9 9 % , 9 5 % C I : 9 2 -1 0 0 ) , t h e D y n a m i k e r L F A ( s e n s i t i v i t y 9 4 % , 9 5 % C I : 7 9 -9 9 ; s p e c i f i c i t y : 9 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. 203 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. 226 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. . https://doi.org/10.1101/2020.07.09.20149864 doi: medRxiv preprint C o n c e r n i n g L F A , o n l y o n e t e s t s h o w e d g o o d p e r f o r m a n c e s f o r b o t h I g G a n d I g M , s h o w i n g 227 t h a t a t h o r o u g h e v a l u a t i o n i s a b s o l u t e l y r e q u i r e d b e f o r e t h e i r c o m m e r c i a l i z a t i o n i n 228 p h a r m a c y o r t h e i r u s e b y p r i v a t e p r a c t i t i o n e r s o u t s i d e r e f e r e n c e d d i a g n o s t i c l a b o r a t o r i e is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. a c u t e a n d e a r l y s u b -a c u t e p h a s e . W e d e m o n s t r a t e d t h e l i m i t e d u s e f u l n e s s o f I g M i n t h e 275 s e r o l o g i c d i a g n o s t i c o f S A R S -C o V -2 . T h e S A R S -C o V -2 s e r o l o g y r e p r e s e n t s a c o m p l e m e n t a r y 276 d i a g n o s t i c t o o l t o R T -P C R f o r t h e C o v i D -1 9 d i a g n o s i s o n p a t i e n t s p r e s e n t i n g b o t h t y p i c a l a n . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 10, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2020. . https://doi.org/10.1101/2020.07.09.20149864 doi: medRxiv preprint Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison 313 with other emerging viruses. Microbes Infect The hallmarks of COVID-19 disease Nowcasting and forecasting the potential domestic and 317 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling 318 study Serological assays for emerging coronaviruses: 320 challenges and pitfalls Molecular and serological investigation of 2019-nCoV infected patients: 322 implication of multiple shedding routes Antibody responses to individual proteins of SARS coronavirus and their 324 neutralization activities. Microbes Infect Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations 326 and Perspectives SARS-CoV-2 specific antibody responses in COVID-19 patients Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 330 Glycoprotein Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies 332 against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in 333 patients with pneumonia due to the SARS coronavirus Diagnostic strategies for SARS-CoV-2 infection and interpretation of 336 microbiological results. CMI, 2020. In press Temporal profiles of viral load in posterior oropharyngeal saliva samples 340 and serum antibody responses during infection by SARS-CoV-2: an observational cohort 341 study. The Lancet Infectious Diseases Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 343 patients Serological differentiation between COVID-19 and SARS infections Indication for SARS-CoV-2 serology: first month follow-up. submitted